Department of Neurology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Neurology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Neurosci Lett. 2021 Nov 20;765:136247. doi: 10.1016/j.neulet.2021.136247. Epub 2021 Sep 14.
Accumulating evidence has shown that sleep disturbance is a common symptom in Alzheimer's disease (AD), which is regarded as a modifiable risk factor for AD. Orexin is a key modulator of the sleep-wake cycle and has been found to be dysregulated in AD patients. The increased orexin in cerebrospinal fluid (CSF) is associated with decreased sleep efficiency and REM sleep, as well as cognitive impairment in AD patients. The orexin system has profuse projections to brain regions that are implicated in arousal and cognition and has been found to participate in the progression of AD pathology. Conversely the orexin receptor antagonists are able to consolidate sleep and reduce AD pathology. Therefore, improved understanding of the mechanisms linking orexin system, sleep disturbance and AD could make orexin receptor antagonists a promising target for the prevention or treatment of AD.
越来越多的证据表明，睡眠障碍是阿尔茨海默病（AD）的常见症状，被认为是 AD 的可改变风险因素。食欲素是睡眠-觉醒周期的关键调节剂，在 AD 患者中发现其失调。脑脊液（CSF）中食欲素的增加与睡眠效率和 REM 睡眠降低以及 AD 患者的认知障碍有关。食欲素系统与参与觉醒和认知的大脑区域有丰富的投射，并被发现参与 AD 病理的进展。相反，食欲素受体拮抗剂能够巩固睡眠并减少 AD 病理。因此，更好地理解将食欲素系统、睡眠障碍和 AD 联系起来的机制，可以使食欲素受体拮抗剂成为预防或治疗 AD 的有希望的靶点。
